PharmaMar begins Phase III ATLANTIS trial of PM1183 combined with doxorubicin to treat SCLC

Spanish biopharmaceutical company PharmaMar has initiated the pivotal Phase III ATLANTIS study of PM1183 combined with doxorubicin versus topotecan or the combination VCR (cyclophosphamide, adriamicine (doxorubicin) and vincristine) to treat small-ce …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news